Moreover, a CD93-targeting monoclonal antibody (mAb) has been demonstrated to reduce tumor growth and enhance the effects of immunotherapy in pancreatic tumors or melanoma via the CD93/IGFBP7 pathway (24). Here, CD93 is linked to neoplasm.